The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.

Harish SeethapathySophia ZhaoDonald F ChuteLeyre ZubiriYaa OppongIan StrohbehnFrank B CortazarDavid E LeafMeghan J MooradianAlexandra-Chloé VillaniRyan J SullivanKerry ReynoldsMeghan E Sise

Published in: Clinical journal of the American Society of Nephrology : CJASN (2019)

AKI is common in patients receiving checkpoint inhibitor therapy. The causes of sustained AKI in this population are heterogenous and merit thorough evaluation. The role of PPI and other nephritis-inducing drugs in the development of sustained AKI needs to be better defined.

Keyphrases

acute kidney injury
risk factors
dna damage
cell cycle
oxidative stress
protein protein
mesenchymal stem cells
cell proliferation
small molecule
cell therapy
clinical evaluation